200 types of specialty coffees from over 18 different countries
worldwide. It is one of the few places coffee drinkers can find
Jamaican Blue Coffee. It recently added AnythingBOOKS.com.
Call CEO J. Scott Sitra @ 719-227-1903 Ext. 102, fax 719-227-1907,
e-mail: email@example.com, or write 3020 North El Paso Rd.,
Suite 103, Colorado Springs, CO 80907. www.anythinginternet.com
[R-7; M-7; L-8+]
Channell Commercial Corporation (NASDAQ/CHNL) designs, manufactures
& sells telecommunications equipment. Products include thermoplastic
& metal fabricated enclosures, fiber optic cable management systems,
coaxial-based passive RF electronics, & advanced copper termination
& connecting components. Facilities are in CA, NC, Toronto, Kent
(UK), & Sydney (Australia).
CHNL sells to such cable & telephone companies as Bell Atlantic,
BellSouth, GTE, Rogers-Canada, TCI, Telecom New Zealand, Time Warner,
Vision Stream-Australia (Telestra), & such OEMs as AMP, DSC, Next
Level, & Siecor. The "curb to the home" segment served by CHNL is
about $500 million, growing about 8%/year
Revenues & earnings have increased every year since 1993.
Revenues for Q2 (6/30/99) were $ 31.3 million, up 36%, with net
income $2.7 million, up from $2.3 million. Current assets at 6/30/99
were $41.1 million, current liabilities were $18.4 million, &
shareholders' equity was $57 million ($6.27 per share).
Call 800-423-1863 or 909-694-9160, fax 909-694-9170, or write 26040
Ynez Rd., PO Box 9022, Temecula, CA 92589-9002, or call Jill Fukuhara
@ CHNL's IR firm, The Financial Relations Board/BSMG Worldwide @
firstname.lastname@example.org www.channellcomm.com [R-7; M-6; L-7]
Conestoga Enterprises, Inc. (NASDAQ NMS/CENI) provides local
exchange telephone service via its Conestoga Telephone Co. (CTT)
& its Buffalo Valley Telephone Co. (BVT); long distance &
access service; & wireless service via its Conestoga Wireless
Company from its PCS (Personal Communications Service) & Conestoga
Mobile Systems from its paging service. It also sells & leases
telephones, PBX equipment, pagers, & PCS wireless telephones.
It provides services in southeastern & central PA, serving more
than 75,000 customers.
CENI has been in business since 1902 & has consistently paid dividends.
For Q2 (6/30/99), operating revenues were $17,880,000 & net income
$1,486,000 ($0.19 per share). During Q2, Conestoga Wireless Co.
added 2,500 subscribers, an increase of 73%.
Conestoga Communications Co. increased its long distance
service customers to over 21,000, adding about 5,000 new customers,
& doubled its CLEC (Competitive Local Exchange) lines to over 2,800
lines in neighboring Bell & PA territories.
CTT & BVT increased their access lines in service by 1,710 during
Q1 & Q2. They had operating revenue growth of $1.7 million. Call
Donald R. Breitenstein, controller @ 610-582-6226, fax 610-582-6338,
e-mail email@example.com, or write CENI @ 202 East First Street,
Birdsboro, PA 19508. www.ceni.com [R-7; M-6; L-7]
ID Biomedical Corporation (NASDAQ/IDBE) is about to rapidly
move from R&D to positive cash flow. It acquires important new technologies
& products, demonstrates their clinical value through advanced R&D,
& partners with senior companies to commercialize them. This strategy
allows IDBE to realize faster near-term revenues, get external R&D
funding, reduce development risk, & realize earnings earlier than
companies that try to do the entire process themselves.
IDBE is emerging in two medical product areas: vaccines, & rapid
gene-based disease detection. It got the go-ahead from the FDA 6/9/99
to proceed with human clinical testing of a vaccine against group
A streptococcus, which causes "strep throat," rheumatic fever, &
"flesh eating disease."
A therapeutic vaccine against AIDS is being developed in collaboration
with professor Arye Rubenstein at the Albert Einstein College Of
Medicine in NY. Small-scale human testing has been accomplished,
& expanded human clinical trials are expected shortly. A vaccine
for the prevention of TB, IDBE's TB vaccine, has been licensed to
Pasteur Merieux Connaught, member of Aventis (formerly Hoechst/Rhone-Poulenc),
& is in clinical development.
The opportunity that will quickly move the company to commercialization
is its VelogeneTM Rapid MRSA Identification Assay. It identifies
antibiotic resistant Staphylococcus aureus (MRSA), one of the hospital
"superbugs." It received FDA marketing approval 6/13/99 & is about
to make its market launch in North America.
After initial culture, this test will detect MRSA in about one
hour, whereas current tests take one to two days. It identifies
the mecA gene responsible for methicillin antibiotic resistance.
In a trial at four hospitals, it correctly identified 99.3% of samples
when compared to conventional susceptibility tests, & 100% when
compared to Polymerase Chain Reaction, the current gold standard
gene identification technology.
Alexon-Trend, Inc. & other subsidiary companies of Sybron International
Corp. (NYSE/SYB) will manufacture, market, & distribute this test,
& IDBE's VRE test in all countries outside of Japan (IDBE is negotiating
Japanese rights with several companies).
Its VelogeneTM Rapid VRE Assay identifies antibiotic resistant
enterococcus, another hospital "superbug," expected to be on the
...continued on next page, click here